OXB Adds Sartorius Veteran Kreuzburg to Board Amid Expansion Push
Event summary
- OXB appoints Dr. Joachim Kreuzburg as Independent Non-Executive Director effective November 23, 2026.
- Kreuzburg previously led Sartorius AG, growing its valuation from EUR 90M to EUR 14B through 24 acquisitions.
- OXB operates a multi-vector CDMO network spanning the UK, France, and the US.
- Kreuzburg currently serves on boards of Carl Zeiss AG, Ottobock SE, and Cube Biotech GmbH.
The big picture
OXB's appointment of Kreuzburg signals a strategic pivot towards aggressive growth, mirroring Sartorius' transformation under his leadership. The move comes as cell and gene therapy CDMOs face increasing pressure to scale globally while maintaining innovation. Kreuzburg's track record in M&A and operational scaling positions OXB to potentially accelerate its market expansion, particularly in the competitive viral vector space.
What we're watching
- Strategic Execution
- How Kreuzburg's M&A expertise will shape OXB's expansion plans across three continents.
- Industry Positioning
- Whether OXB can leverage Kreuzburg's network to strengthen its competitive stance in viral vector manufacturing.
- Governance Impact
- The pace at which Kreuzburg can influence OXB's operational and commercial strategies.